Leonardo CC, Mendes M, Ahmad AS, Dore S. Efficacy of prophylactic flavan-3-ol in permanent focal ischemia in 12-mo-old mice. Am J Physiol Heart Circ Physiol. 2015;308:H583–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67:1–12.

Article  PubMed  Google Scholar 

Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. JAMA. 2015;314:1255–63.

Article  CAS  PubMed  Google Scholar 

Anderson L, Brown JP, Clark AM, Dalal H, Rossau HK, Bridges C, et al. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev. 2017;6:CD008895.

PubMed  Google Scholar 

Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588–93.

Article  PubMed  Google Scholar 

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.

Article  CAS  PubMed  Google Scholar 

Dong OM, Friede KA, Chanfreau-Coffinier C, Voora D. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2023;9:249–57.

Article  PubMed  Google Scholar 

Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836–42.

Article  PubMed  PubMed Central  Google Scholar 

Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng X, Deng L, Zhang Y, Chang L. [Regional citrate versus heparin anticoagulation in continuous renal replacement therapy in critically ill patients: a meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:982–7.

PubMed  Google Scholar 

Ranucci M, Ballotta A, Kandil H, Isgro G, Carlucci C, Baryshnikova E, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275.

Article  PubMed  PubMed Central  Google Scholar 

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.

Article  PubMed  Google Scholar 

Elgendy IY, Capodanno D. Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end? J Thorac Dis. 2017;9:4305–7.

Article  PubMed  PubMed Central  Google Scholar 

Cohen M, Sohal S. Editorial: bivalirudin versus unfractionated heparin in acute myocardial infarction: why are we still debating? Cardiovasc Revasc Med. 2024;61:62–3.

Article  PubMed  Google Scholar 

Ansari MM, Garcia DC, Toussaint JL, Mendoza C, Alfonso C, Cohen MG, et al. Comparison of bivalirrudin and heparin use for acute myocardial infarction: a meta-analysis of the randomized trials. J Am Coll Cardiol. 2014;64:460–71.

Article  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane; 2024. Available from www.training.cochrane.org/handbook.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

Omerovic E, James S, Råmundal T, Fröbert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-outcomes at two years. Cardiovasc Revasc Med. 2024;66:43–50.

Article  PubMed  Google Scholar 

Song H, Sun Y, Liu M. Comparison of the application effect and safety of bivalirudin and unfractionated heparin in PCI surgery for patients with acute myocardial infarction. Chinese and Foreign Medical Journal. 2023;42:140–3+48.

Google Scholar 

Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400:1847–57.

Article  CAS  PubMed  Google Scholar 

James S, Koul S, Andersson J, Angerås O, Bhiladvala P, Calais F, et al. Bivalirudin versus heparin monotherapy in ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2021;14: e008969.

Article  CAS  PubMed  Google Scholar 

Wester A, Attar R, Mohammad MA, Isma N, James S, Omerovic E, et al. Bivalirudin versus heparin monotherapy in elderly patients with myocardial infarction: a prespecified subgroup analysis of the VALIDATE-SWEDEHEART trial. Circ Cardiovasc Interv. 2020;13: e008671.

Article  CAS  PubMed  Google Scholar 

Li Y, Liu P. Comparative study on the efficacy of unfractionated heparin and bivalirudin in patients with acute myocardial infarction undergoing PCI. Smart Health. 2020;6:101–2+05.

Google Scholar 

Erlinge D, Koul S, Omerovic E, Fröbert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019;8:492–501.

Article  PubMed  Google Scholar 

Li C, Xu R, Shen Y, Dai Y, Zhang F, Ma J, et al. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: a single-center pilot study. Catheter Cardiovasc Interv. 2018;91:679–85.

Article  PubMed  Google Scholar 

Czarny MJ, Hwang CW, Naiman DQ, Lemmon CC, Hasan RK, Wang T, et al. Heparin versus bivalirudin for non-primary percutaneous coronary intervention: a post-hoc analysis of the CPORT-E trial. Catheter Cardiovasc Interv. 2017;90:366–77.

Article  PubMed  Google Scholar 

Lima FV, Gruberg L, Aslam U, Ramgadoo M, Clase K, Trevisan A, et al. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention. J Interv Cardiol. 2018;31:177–84.

Article  PubMed  Google Scholar 

Wang H, Li Y, Cong H, Ding S, Liu B, Li L, et al. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: a subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. Catheter Cardiovasc Interv. 2017;89:1157–65.

Article  PubMed  Google Scholar 

Erlinge D, Koul S, Eriksson P, Scherstén F, Omerovic E, Linder R, et al. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). Am Heart J. 2016;175:36–46.

Article  CAS  PubMed  Google Scholar 

Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, et al. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015;8:414–23.

Article  PubMed  Google Scholar 

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313:1336–46.

Article  CAS  PubMed  Google Scholar 

Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg NA, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding. Int J Angiol. 2014;23:227–32.

Article  PubMed  PubMed Central  Google Scholar 

Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014;35:2285–94.

Article  CAS  PubMed  Google Scholar